Online citations, reference lists, and bibliographies.

2012 American College Of Rheumatology Guidelines For Management Of Gout. Part 2: Therapy And Antiinflammatory Prophylaxis Of Acute Gouty Arthritis.

Dinesh Khanna, Puja P. Khanna, John D Fitzgerald, Manjit K Singh, Sangmee Sharon Bae, Tuhina Neogi, Michael H. Pillinger, Joan Merill, Susan Lee, Shraddha Prakash, Marian Kaldas, Maneesh Gogia, Fernando Pérez-Ruiz, Will Taylor, Frédéric Lioté, Hyon Choi, Jasvinder A. Singh, Nicola Dalbeth, Sanford Sandy Kaplan, Vandana Dua Niyyar, Danielle Jones, Steven A Yarows, Blake Roessler, Gail Kerr, Charles King, Gerald E. Levy, Daniel E. Furst, N. Lawrence Edwards, Brian Mandell, Harold R. Schumacher, Mark Robbins, Neil S Wenger, Robert Terkeltaub
Published 2012 · Medicine
Referenced 1 time by Citationsy Users
Cite This
Download PDF
Analyze on Scholarcy
Share
In response to a request for proposal from the American College of Rheumatology (ACR), our group was charged with developing non-pharmacologic and pharmacologic guidelines for treatments in gout that are safe and effective, i.e., with acceptable risk-benefit ratio. These guidelines for the management and anti-inflammatory prophylaxis of acute attacks of gouty arthritis complements our manuscript on guidelines to treat hyperuricemia in patients with evidence of gout (or gouty arthritis) (1). Gout is the most common cause of inflammatory arthritis in adults in the USA. Clinical manifestations in joints and bursa are superimposed on top of local deposition of monosodium urate crystals. Acute gout characteristically presents as self-limited, attack of synovitis (also called “gout flares”). Acute gout attacks account for a major component of the reported decreased health-related quality of life in patients with gout (2, 3). Acute gout attacks can be debilitating and are associated with decreased work productivity (4, 5). Urate lowering therapy (ULT) is a cornerstone in the management of gout, and, when effective in lowering serum urate (SUA), is associated with decreased risk of acute gouty attacks (6). However, during the initial phase of ULT, there is an early increase in acute gout attacks, which has been hypothesized due to remodeling of articular urate crystal deposits as a result of rapid and substantial lowering of ambient urate concentrations (7). Acute gout attacks attributable to the initiation of ULT may contribute to non-adherence in long-term gout treatment, as reported in recent studies (8). In order to systematically evaluate a broad spectrum of acute gouty arthritis, we generated multifaceted case scenarios to elucidate decision making based primarily on clinical and laboratory test-based data that can be obtained in a gout patient by both non-specialist and specialist health care providers in an office practice setting. This effort was not intended to create a novel classification system of gout, or new gout diagnostic criteria, as such endeavors are beyond the scope of this work. Prior gout recommendations and guidelines, at the independent (i.e, non pharmaceutical industry-sponsored) national or multinational rheumatology society level, have been published by EULAR (9, 10), the Dutch College of General Practitioners (11), and the British Society for Rheumatology (BSR)(12). The ACR requested new guidelines, in view of the increasing prevalence of gout (13), the clinical complexity of management of gouty arthritis imposed by co-morbidities common in gout patients (14), and increasing numbers of treatment options via clinical development of agents(15–17). The ACR charged us to develop these guidelines to be useful for both rheumatologists and other health care providers on an international level. As such, this process and resultant recommendations, involved a diverse and international panel of experts. In this manuscript, we concentrate on 2 of the 4 gout domains that the ACR requested for evaluation of pharmacologic and non-pharmacologic management approaches: (i) analgesic and anti-inflammatory management of acute attacks of gouty arthritis, and (ii) pharmacologic anti-inflammatory prophylaxis of acute attacks of gouty arthritis. Part I of the guidelines focused on systematic non-pharmacologic measures (patient education, diet and lifestyle choices, identification and management of co-morbidities) that impact on hyperuricemia, and made recommendations on pharmacologic ULT in a broad range of case scenarios of patients with disease activity manifested by acute and chronic forms of gouty arthritis, including chronic tophaceous gouty arthropathy(1). Each individual and specific statement is designated as a “recommendation”, in order to reflect the non-prescriptive nature of decision making for the hypothetical clinical scenarios. So that the voting panel could focus on gout treatment decisions, a number of key assumptions were made, as described in Part I of the guidelines (1). Importantly, each proposed recommendation assumed that correct diagnoses of gout and acute gouty arthritis attacks had been made for the voting scenario in question. For treatment purposes, it was also assumed that treating clinicians were competent, and considered underlying medical comorbidities (including diabetes, gastrointestinal disease, hypertension, and hepatic, cardiac, and renal disease), and potential drug toxicities and drug-drug interactions, when making both treatment choicesand dosing decisions on chosen pharmacologic interventions. The RAND/UCLA methodology used here emphasizes level of evidence, safety, and quality of therapy, and excludes analyses of societal cost of health care. As such, the ACR gout guidelines are designed to reflect best practice, supported either by level of evidence or consensus-based decision-making. These guidelines cannot substitute for individualized, direct assessment of the patient, coupled with clinical decision making by a competent health care practitioner. The motivation, financial circumstances, and preferences of the gout patient also need to be considered in clinical practice, and it is incumbent on the treating clinician to weigh the issues not addressed by this methodology, such as treatment costs, when making management decisions. Last, the guidelines for gout management presented herein were not designed to determine eligibility for health care cost coverage by third party payers.
This paper references
10.1185/03007999109111513
Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout.
Alessia Maccagno (1991)
High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first Khanna et al. Page 13 Arthritis Care Res (Hoboken)
RA Terkeltaub (2010)
NSAID prescribing precautions.
Amanda L. Risser (2009)
Methodology Perspectives, AHCPR
R. Brook (1994)
Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.
Gregory C Borstad (2004)
Developing a provisional definition of a flare in patients with established gout. Arthritis Rheum
A L Gaffo (2012)
10.1002/ART.33392
Erratum: Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors; Association of PPP2CA Polymorphisms With Systemic Lupus Erythematosus Susceptibility in Multiple Ethnic Groups
Robert Terkeltaub (2011)
10.1002/acr.21641
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Jasvinder A. Singh (2012)
10.1080/15257770802136032
Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy
Michael A. Becker (2008)
10.1186/ar2143
A pilot study of IL-1 inhibition by anakinra in acute gout
Alexander K L So (2007)
kinra ’ s efficacy is variable in refractory gout : report of ten cases
K Chen (2010)
10.1111/j.1445-5994.1987.tb01232.x
Does colchicine work? The results of the first controlled study in acute gout.
Michael John Ahern (1987)
10.1592/phco.28.4.437
Comparison of drug adherence rates among patients with seven different medical conditions.
Becky A. Briesacher (2008)
10.1097/01.rhu.0000135555.83088.a2
Dosing of antirheumatic drugs in renal disease and dialysis.
A S Swarup (2004)
update of the 2008 American College of Rheumatology recommendations for the use of disease - modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
JM Grossman (2012)
10.1002/art.20405
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.
Akira Shoji (2004)
10.1093/rheumatology/kem056a
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.
Kelsey M Jordan (2007)
10.1002/art.1780170517
Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients.
Harold E. Paulus (1974)
[Summary of the Dutch College of General Practitioners' "Gout" Standard].
A. C. M. Romeijnders (2002)
10.1161/CIRCULATIONAHA.105.167586
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Sharon Ann Hunt (2005)
10.1016/j.amjmed.2010.09.012
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
Robert T Keenan (2011)
10.1016/S0140-6736(08)60799-0
Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial
Hein J.E.M. Janssens (2008)
10.1002/art.20007
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
Bernard Rubin (2004)
10.1056/NEJMoa050373
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Michael A. Becker (2005)
10.1002/art.27327
High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.
Robert Terkeltaub (2010)
10.1002/art.33483
Developing a provisional definition of flare in patients with established gout.
Angelo Lino Gaffo (2012)
10.1016/0049-0172(90)90070-V
Systemic steroid therapy for acute gout: a clinical trial and review of the literature.
G D Groff (1990)
The RAND/UCLA Appropriateness Method
R. Brook (1994)
Local ice therapy during bouts of acute gouty arthritis.
Naomi Schlesinger (2002)
[Summary of the Dutch College of General Practitioners' practice guideline, "Examination of the neonate"].
Sander Flikweert (2002)
10.6032/GNAM.37.139
American College of Rheumatology guidelines for management of gout
Dinesh N. Khanna (2013)
10.1002/14651858.CD005521.pub2
Systemic corticosteroids for acute gout.
Hein J.E.M. Janssens (2008)
10.1111/j.1524-4733.2007.00173.x
The impact of gout on work absence and productivity.
Nathan L. Kleinman (2007)
10.1016/j.amjopharm.2011.07.004
Management of gout in the older adult.
Michelle A. Fravel (2011)
10.1136/bmj.324.7352.1488
Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis
H Ralph Schumacher Jr (2002)
10.1016/J.LPM.2011.02.043
Nouveaux traitements de la goutte
Pascal Richette (2011)
10.1016/j.clinthera.2011.01.008
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Robert L. Wortmann (2010)
10.3899/jrheum.110916
Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial
Harold R. Schumacher (2012)
10.1682/JRRD.2006.05.0051
Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents.
Katherine R. Jones (2007)
10.1186/ar2978
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Michael A. Becker (2010)
Colchicine dosing guidelines for gout patients with varying degrees of renal impairment based on pharmacokinetic data [abstract
S Wason (2011)
FDA prescribing information for COLCRYS
(2009)
Systemic corticosteroids for acute gout (Review)
Hein J.E.M. Janssens (2008)
10.1002/art.27600
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
Alexander K L So (2010)
10.1080/15257770.2011.596499
Comorbidities in Patients with Gout
Naomi Ichikawa (2011)
Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study.
Roy Altman (1988)
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis
JM Grossman (2010)
10.1185/03007995.2010.533647
Chronic gout: epidemiology, disease progression, treatment and disease burden
Richard Alan Brook (2010)
10.1186/ar3297
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study
Naomi Schlesinger (2011)
10.1185/030079906X112606
The economic burden of gout on an employed population
Richard Alan Brook (2006)
Methodology Perspectives, AHCPR 1994
R Brook
10.1002/art.23721
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Kenneth G. Saag (2008)
10.2165/11206330-000000000-00000
Oral Colchicine (Colcrys®) in the Treatment and Prophylaxis of Gout
Lily P. H. Yang (2010)
10.1002/art.20102
Quality of care indicators for gout management.
Ted R Mikuls (2004)
10.1002/art.30389
Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors.
Robert Terkeltaub (2011)
ACC / AHA
SA Hunt (2005)
Lessons learned from a multiple-dose postoperative analgesic trial. Pain 2004;109:103–9
TR Mendoza (2004)
Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.
J A Alloway (1993)
10.1136/ard.2010.144063
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
Naomi Schlesinger (2011)
10.1097/MEJ.0b013e32832a083f
Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis
Giles N Cattermole (2009)
10.1016/j.pain.2004.01.015
Lessons learned from a multiple-dose post-operative analgesic trial
Tito R. Mendoza (2004)
update of the 2008 American College of Rheumatology recommendations for the use of disease - modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
JA Singh (2012)
10.1016/j.semarthrit.2010.03.001
Anakinra's efficacy is variable in refractory gout: report of ten cases.
Kun Ho Chen (2010)
10.1136/ard.2006.055251
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)
Weiya Zhang (2006)
Sulindac in the treatment of acute gout arthritis.
George N. Karachalios (1982)
10.1136/ard.2006.055269
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
Weiya Zhang (2006)
10.1136/annrheumdis-2012-201676
Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study
Frances S. Rees (2013)
10.1002/acr.21772
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
Dinesh Khanna (2012)
Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthri
HR Schumacher (2002)
10.3899/jrheum.090371
Progress in Measurement Instruments for Acute and Chronic Gout Studies
Rebecca Grainger (2009)
10.1016/j.lpm.2011.02.043
[New therapeutic options for gout].
Pascal Richette (2011)
10.1016/B978-1-4377-2864-4.10018-1
Health-Related Quality of Life and Outcome Measures in Gout
Puja P. Khanna (2012)
10.1371/journal.pone.0016780
NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies
Luis Garcia Rodriguez (2011)
10.1093/rheumatology/kem090
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
Roland Ernst Willburger (2007)
10.1002/art.20422
Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics.
Kenneth G. Saag (2004)
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy
庄司 晃 (2005)
10.1002/art.1780391104
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Marc C. Hochberg (2001)
Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide.
Cristalina Fernández (1999)
10.1002/art.30520
Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.
Yanyan Zhu (2011)
American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
JA Singh (2012)
10.1016/j.annemergmed.2006.11.014
Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial
Chi Yin Man (2007)
10.1136/ard.36.1.80
Multicentre trial of naproxen and phenylbutazone in acute gout.
R A Sturge (1977)
parison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis
JA Alloway (1993)
A survey of current evaluation and treatment of gout.
Naomi Schlesinger (2006)
10.1002/art.33412
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
Harold R. Schumacher (2012)
10.1038/nrrheum.2009.236
Update on gout: new therapeutic strategies and options
Robert Terkeltaub (2010)
10.1001/jama.2011.1169
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
John S. Sundy (2011)
10.1002/acr.20295
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.
Jennifer M. Grossman (2010)
10.3111/13696998.2010.540874
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy
N. Lawrence Edwards (2011)



This paper is referenced by
10.1016/S1297-319X(15)30004-X
Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases.
Annalina Avram (2015)
10.1038/nrrheum.2017.126
Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)
Nicola Dalbeth (2017)
10.1016/j.semarthrit.2017.09.007
Medication adherence among patients with gout: A systematic review and meta-analysis.
L. E. Scheepers (2018)
10.3892/etm.2019.7816
Aberrant expression of long non-coding RNAs in peripheral blood mononuclear cells isolated from patients with gouty arthritis
Xiaowu Zhong (2019)
10.1155/2019/9456318
A Traditional Clinic Chinese Medicine Prescription Qu-Zhuo-Tong-Bi (QZTB) Alleviates Gouty Arthritis in Model Rats
Huiqing Lv (2019)
10.26724/2079-8334-2017-4-62-197-203
HYPOURICEMIC THERAPY FOR PREVENTION AND TREATMENT OF THE STORAGE: ACTUAL STATE OF THE PROBLEM
Maksym V Tkachenko (2017)
10.1097/BOR.0000000000000141
Overcoming adherence issues and other barriers to optimal care in gout
Navine Nasser-Ghodsi (2015)
10.1093/rheumatology/kez203
Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval.
Tristan Pascart (2019)
10.1007/s00330-016-4237-2
Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT
Tim Finkenstaedt (2016)
10.1007/s00296-017-3777-3
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Carly A. Janssen (2017)
10.1002/ptr.6111
Liver enzyme abnormalities of inpatients with rheumatic diseases: A 10‐year retrospective study in a Korean medicine hospital
Hyeonhoon Lee (2018)
10.1007/978-3-642-54493-4_15
Rheumatoid Arthritis, Gout, and Spondyloarthritis in Foot and Ankle
Sang Heon Lee (2016)
10.1007/978-3-319-32700-6_57-1
Crystal-Induced Arthritis
Nages Nagaratnam (2017)
10.3899/jrheum.141542
Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study
Jiunn-Horng Chen (2015)
10.1007/s11926-014-0492-x
The Gouty Tophus: a Review
Ashika Chhana (2015)
10.1016/j.clinthera.2014.07.017
Mechanism of action of colchicine in the treatment of gout.
Nicola Dalbeth (2014)
10.1097/RHU.0b013e31827cd9da
Guidelines and algorithms: a call for evaluation of their use and effects.
Harold R. Schumacher (2012)
10.1007/s12688-014-0016-9
Diagnose und Therapiestandard der Gicht in Österreich
Judith Sautner (2015)
10.1016/j.schres.2015.07.047
Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort
Ophélia Godin (2015)
10.1016/j.amjmed.2014.12.010
Colchicine: old and new.
Anastasia Slobodnick (2015)
10.1111/jch.12413
Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension.
Liza Wilson (2014)
10.1016/B978-0-7020-4769-5.00003-0
Chapter 3 – Gout
Keith Rome (2015)
10.1002/acr.22336
Medication adherence in gout: a systematic review.
Mary A De Vera (2014)
10.1016/B978-1-4377-1738-9.00095-5
95 – Clinical Features and Treatment of Gout
Christopher M. Burns (2013)
10.1016/j.jbspin.2016.02.012
New therapeutic approach to hyperuricemia and gout in the light of recommendations.
Frédéric Lioté (2016)
10.1016/J.RCENG.2016.06.004
Ultrasound in the diagnosis of asymptomatic hyperuricemia and gout
Juan García Puig (2016)
10.1097/RHU.0000000000000561
Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management
Brian W Coburn (2017)
10.1080/13696998.2020.1757456
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Sil-Ling Pruis (2020)
10.1016/j.maturitas.2018.10.012
Gout - An update of aetiology, genetics, co-morbidities and management.
Philip C Robinson (2018)
Prevalence of hyperuricemia in very high cardiovascular risk patients — a single centre retrospective cohort study
Marcin Tomasz Wełnicki (2019)
10.4081/reumatismo.2013.4
Italian Society of Rheumatology recommendations for the management of gout.
Maria Manara (2013)
10.3904/KJM.2018.93.4.344
통풍의 새로운 진단 분류 기준과 치료 지침
송정수 (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar